The Food and Drug Administration's FDA or Agency Center for Drug Evaluation and Research CDER is proposing to withdraw approval of two abbreviated new drug applications ANDAs and is announcing an opportunity for the ANDA holder to request a hearing on this proposal. The basis for the proposal is that the ANDA holder has repeatedly failed to file required annual reports for those ANDAs.